What does 2019 have in store for Pharma?
Crystec’s CEO, Paul Thorning, has contributed to an article by UBM featuring the big issues affecting Pharma for 2019, according to key opinion leaders in the industry. Contributors include representatives from PharmSource, Catalent Pharma Solutions and NIBRT.
Crystec’s hot topic for 2019 is supergenerics with the potential to outperform NCEs (New Chemical Entities). With a continuous focus on developing strongly differentiated products, both in-house and for our clients, Crystec are leading the way in identifying new routes to improved product performance. By applying mSAS (modified Supercritical Anti-Solvent) technology to existing and new molecules, we are able to engineer particles with optimal solid-state form, particle size and shape, and to combine multiple drugs in simple formulations. Reformulation can have transformative effects on the bioavailability of a molecule, often leading to reduced doses, increased patient tolerability and opportunities for more patient friendly routes of administration.
The full article can be found on the CPhI website (https://www.cphi.com/europe/visit/news-and-updates/pharma-outlook-12-trends-watch-2019).
To find out more about how mSAS can be applied to support your product development, please get in touch (firstname.lastname@example.org).